Defining When Nusinersen Starts to Work: Time to Clinical Benefit in Patients with SMA Types 1–3 from a Real-World Cohort in China

Ying Wu(Peking University), Cuijie Wei(Peking University), Yu Zhang(Institute of Biophysics), Yuan Wu(Peking University), S Li(University of Hong Kong), H Xiong(Peking University), Jie Zhang(Peking University), 范燕彬(Peking University), Hui Dong(Peking University), 杨晓玲(Peking University)
Diagnostics
June 12, 2026
10.3390/diagnostics16121828
Cited by 0

Related Papers

Highly efficient photocatalytic degradation of norfloxacin via Bi2Sn2O7/PDIH Z-scheme heterojunction: Influence and mechanism
|Journal of Hazardous Materials|2022|148
<scp>CAG</scp> Repeat Expansion in <scp><i>THAP11</i></scp> Is Associated with a Novel Spinocerebellar Ataxia
|Movement Disorders|2023|51
Phenotypic spectrum of mutations in <i><scp>IBA57</scp></i>, a candidate gene for cavitating leukoencephalopathy
|Clinical Genetics|2017|32
Excess sarcoplasmic reticulum-mitochondria calcium transport induced by Sphingosine-1-phosphate contributes to cardiomyocyte hypertrophy
|Biochimica et Biophysica Acta (BBA) - Molecular Cell Research|2021|12
Impact of epilepsy surgery on developmental trajectories of children under 3 years of age
|Developmental Medicine & Child Neurology|2024|4